利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.054 秒)

    Identification, isolation and elimination of cancer stem cells
    14.
    发明授权
    Identification, isolation and elimination of cancer stem cells 有权
    识别，分离和消除癌症干细胞

    公开(公告)号：US07816088B2

    公开(公告)日：2010-10-19

    申请号：US10579540

    申请日：2004-12-06

    申请人： Catriona Helen M. Jamieson ,  Laurie Ailles ,  Irving L. Weissman

    发明人： Catriona Helen M. Jamieson ,  Laurie Ailles ,  Irving L. Weissman

    IPC分类号： G01N33/53 ,  C12N5/08

    CPC分类号： G01N33/57426 ,  C12N5/0695 ,  G01N33/5011 ,  G01N2333/70589 ,  G01N2333/70596 ,  G01N2333/715

    摘要： Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the bcatenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.

    摘要翻译： 提供了白血病干细胞的分离群体。 这些细胞可用于实验评价，也可用作谱系和细胞特异性产物的来源，也可用于发现影响它们的因子或分子。 白血病干细胞的检测可用于预测疾病进展，复发和耐药发展。 LSC的增殖可通过干扰bcatenin途径的活化来抑制。 通过差异分析血液样品以分配一个或多个造血干细胞或祖细胞亚群，为白血病和白血病的临床分期提供方法。

    Methods of identifying and isolating stem cells and cancer stem cells
    16.
    发明授权
    Methods of identifying and isolating stem cells and cancer stem cells 失效
    识别和分离干细胞和癌症干细胞的方法

    公开(公告)号：US07622255B2

    公开(公告)日：2009-11-24

    申请号：US11799817

    申请日：2007-05-02

    申请人： Catriona Helen M. Jamieson ,  Laurie Ailles ,  Tannishtha Reya ,  Irving L. Weissman

    发明人： Catriona Helen M. Jamieson ,  Laurie Ailles ,  Tannishtha Reya ,  Irving L. Weissman

    IPC分类号： C12Q1/68 ,  C12Q1/02 ,  C12N15/00

    CPC分类号： C12Q1/6897 ,  C12N5/0647 ,  C12Q1/6881 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156

    摘要： Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

    摘要翻译： 提供了用于鉴定干细胞和癌症干细胞的方法和组合物。 β-连环蛋白也被鉴定为用于开发针对造血肿瘤，即白血病和淋巴瘤细胞的治疗部分的靶标，其可以包括针对β-连环蛋白的筛选测定或β-连环蛋白信号传导途径的成员。 造血细胞中的细胞增殖可以通过将稳定的β-连环蛋白引入造血细胞而改变，造血细胞在其经历凋亡的能力方面发生改变，但尚未完全转化。 永生化细胞可用于筛选测定，以及造血细胞经历转化的途径的分析。

    Mammalian megakaryocyte progenitor cell
    18.
    发明授权
    Mammalian megakaryocyte progenitor cell 有权
    哺乳动物巨核细胞祖细胞

    公开(公告)号：US07494807B2

    公开(公告)日：2009-02-24

    申请号：US10661455

    申请日：2003-09-12

    申请人： Thanyaphong Na Nakorn ,  Toshihiro Miyamoto ,  Irving L. Weissman

    发明人： Thanyaphong Na Nakorn ,  Toshihiro Miyamoto ,  Irving L. Weissman

    IPC分类号： C12N5/00

    CPC分类号： C12N5/0644 ,  C12N2503/02

    摘要： A substantially enriched mammalian hematopoietic cell population is provided, which is characterized as a progenitor cell committed to the megakaryocyte lineage. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD9 and CD41, in conjunction with other markers expressed on lineage committed progenitor cells. These cells give rise exclusively to megakaryocytes and platelets, as evidenced by their growth and differentiation in vitro and in vivo.

    摘要翻译： 提供了基本上富集的哺乳动物造血细胞群，其特征在于致力于巨核细胞谱系的祖细胞。 提供了用于分离和培养这些细胞的方法。 细胞富集方法使用特异性识别CD9和CD41的试剂，与在谱系确定的祖细胞上表达的其他标志物结合。 这些细胞只能产生巨核细胞和血小板，如体外和体内生长和分化所证明。

    Mammalian myeloid progenitor cell subsets
    20.
    发明授权
    Mammalian myeloid progenitor cell subsets 有权
    哺乳动物骨髓祖细胞亚群

    公开(公告)号：US07300760B2

    公开(公告)日：2007-11-27

    申请号：US10737576

    申请日：2003-12-15

    申请人： Irving L. Weissman ,  David Jeffrey Traver ,  Koichi Akashi ,  Markus Gabriel Manz ,  Toshihiro Miyamoto

    发明人： Irving L. Weissman ,  David Jeffrey Traver ,  Koichi Akashi ,  Markus Gabriel Manz ,  Toshihiro Miyamoto

    IPC分类号： G01N33/53 ,  C12N5/00 ,  C12N5/02

    CPC分类号： C12N5/0647 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/26 ,  C12N2503/00 ,  C12Q1/6881 ,  C12Q2600/158

    摘要： A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7Rα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

    摘要翻译： 提供了基本上富集的哺乳动物造血细胞亚群，其特征在于骨髓谱系的祖细胞活性，但缺乏分化成淋巴谱系的潜力。 该群体进一步分为特定的骨髓祖细胞亚群，包括常见的髓系祖细胞（CMP），巨核细胞/红细胞祖细胞（MEP）和粒细胞/单核细胞谱系祖细胞（GMP）。 提供了用于分离和培养这些亚群体的方法。 CMP群体产生所有骨髓谱系，并且可以产生专门致力于红细胞/巨核细胞或骨髓单核细胞谱系的两个另外的和可分离的祖细胞群体。 细胞富集方法采用特异性识别Thy-1的试剂; 和IL-7Rα，与在谱系承诺细胞上表达的其他标志物结合。 这些细胞产生各种骨髓细胞，包括巨核细胞，粒细胞，树突状细胞和红细胞，其体外和体内的生长和分化证明。